ANIK vs PCRX
ANIK: Anika Therapeutics manufactures and markets hyaluronic acid (HA)-based medical products for orthopedic pain management, tissue regeneration, and non-orthopedic surgical applications. PCRX: Pacira BioSciences is a non-opioid pain management company commercializing injectable, device, and gene therapy treatments for postsurgical and osteoarthritis pain.
Side-by-side fundamentals
| Metric | ANIK | PCRX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $15.01 | $25.59 | |
| Market cap as of 2026-07-23 | $199M | $1.0B | |
| P/E as of 2026-07-23 | n/a | 194.68 | |
| PEG as of 2026-07-23 | n/a | 17.75 | |
| Net margin as of 2026-07-23 | -9.5% | +0.7% | PCRX higher |
| Gross margin as of 2026-07-23 | +58.6% | +79.3% | PCRX higher |
| Operating margin as of 2026-07-23 | -10.5% | +0.1% | PCRX higher |
| ROE as of 2026-07-23 | -7.7% | +0.7% | PCRX higher |
| ROA as of 2026-07-23 | -5.9% | +0.4% | PCRX higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.56 | ANIK lower |
| Revenue growth (YoY) as of 2026-07-23 | -15.4% | +4.6% | PCRX higher |
| Revenue CAGR (3y) SEC XBRL | -0.3% | +2.9% | PCRX higher |
| Beta as of 2026-07-23 | 0.22 | 0.26 | |
| 1-year return as of 2026-07-22 close | +41.8% | +14.1% | ANIK higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.